Global Pegfilgrastim Market Size By Type (Pegfilgrastim, Pegfilgrastim Biosimilar), By Application (Hospital, Drug store), By Region, And Segment Forecasts, 2023 to 2032

The Global Pegfilgrastim Market was valued at USD 6.2 billion in 2023 and is projected to surpass USD 10.1 billion by 2031, expanding at a CAGR of 6.4% during the forecast period from 2023 to 2031. Pegfilgrastim, a long-acting form of filgrastim, is widely used to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy. The increasing prevalence of cancer, rising adoption of biosimilars, and growing awareness about infection control during cancer treatments are fueling market expansion globally.

Drivers:

1. Rising Incidence of Cancer:

The growing global cancer burden is directly driving the demand for supportive oncology therapies such as pegfilgrastim. As chemotherapy remains a mainstay for many cancer types, the use of pegfilgrastim to mitigate neutropenia is seeing consistent growth.

2. Shift Toward Biosimilars:

With multiple pegfilgrastim biosimilars receiving regulatory approvals across regions like the U.S., Europe, and Asia-Pacific, their increased uptake due to cost-effectiveness is catalyzing market growth.

3. Expansion of Oncology Healthcare Infrastructure:

Governments and private sectors in emerging economies are increasingly investing in cancer care, which includes access to advanced biologics and biosimilars, contributing to the wider availability and usage of pegfilgrastim.

Restraints:

1. High Cost of Biologics:

Despite biosimilar availability, pegfilgrastim remains an expensive treatment, which could limit its access, especially in low- and middle-income countries.

2. Stringent Regulatory Landscape:

Biosimilar development and commercialization require extensive clinical studies, quality checks, and regulatory reviews. These hurdles may slow down the launch of new biosimilars in some regions.

Opportunity:

1. Growing Acceptance of Biosimilars in Oncology:

Healthcare providers and patients are increasingly accepting biosimilars as effective alternatives to branded biologics, creating a promising pathway for market expansion, especially in cost-sensitive markets.

2. Expanding Access Through Self-administration Devices:

Advancements in on-body injector devices that allow patients to self-administer pegfilgrastim at home are improving treatment adherence and convenience, especially in outpatient settings.

Market by System Type Insights:

Based on system type, the Prefilled Syringe segment dominated the market in 2023. The high convenience, accurate dosing, and ease of use make prefilled syringes a preferred delivery method among healthcare providers and patients. However, the On-body Injector segment is expected to register the fastest growth due to increased home-based care trends and patient comfort.

Market by End-use Insights:

In terms of end-use, the Hospital Pharmacies segment accounted for the largest market share in 2023. Hospitals remain the primary point of care for chemotherapy and supportive treatments, making them major distribution hubs for pegfilgrastim. Meanwhile, Retail Pharmacies and Specialty Clinics are anticipated to gain traction as biosimilar penetration increases in outpatient settings.

Market by Regional Insights:

North America led the global pegfilgrastim market in 2023, driven by a high incidence of cancer, early adoption of biosimilars, and the presence of key manufacturers. Asia-Pacific is projected to witness the highest CAGR during the forecast period, owing to increasing healthcare investments, rising cancer prevalence, and favorable regulatory policies supporting biosimilars in countries like India, China, and South Korea.

Competitive Scenario:

Key players operating in the global pegfilgrastim market include:

Amgen Inc.

Coherus BioSciences

Sandoz (a Novartis division)

Pfizer Inc.

Mylan N.V. (part of Viatris)

Biocon Biologics Ltd.

Fresenius Kabi

Intas Pharmaceuticals Ltd.

These companies are investing in R&D, expanding manufacturing capacities, and pursuing strategic partnerships to strengthen their biosimilar portfolios. For instance:

In 2023, Coherus BioSciences expanded distribution of UDENYCA® across more oncology clinics in North America.

In 2024, Biocon Biologics secured approvals for its pegfilgrastim biosimilar in several European countries.

In 2025, Sandoz initiated Phase 3 trials for a new pegfilgrastim formulation designed for rapid absorption and improved bioavailability.

Scope of Work – Global Pegfilgrastim Market

Key Market Developments:

2023: Amgen launched a digital education campaign to promote awareness of Neulasta® and on-body injector usage.

2024: Mylan-Viatris expanded its pegfilgrastim biosimilar distribution through a new licensing agreement with a major Asian distributor.

2025: Pfizer received FDA approval for a next-generation biosimilar with enhanced temperature stability for longer shelf-life.

FAQs:

1) What is the current market size of the Global Pegfilgrastim Market?

The market size was USD 6.2 billion in 2023.

2) What is the major growth driver of the Global Pegfilgrastim Market?

The increasing incidence of cancer and rising adoption of biosimilars are key growth drivers.

3) Which is the largest region during the forecast period in the Global Pegfilgrastim Market?

North America held the largest share in 2023, while Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Pegfilgrastim Market?

The Prefilled Syringe segment led the market in 2023 by system type.

5) Who are the key market players in the Global Pegfilgrastim Market?

Key players include Amgen Inc., Coherus BioSciences, Sandoz, Mylan-Viatris, Biocon, and Pfizer.